Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies?

dc.authoridYILMAZ, Ibrahim/0000-0003-2003-6337
dc.authoridDOGAN, Mustafa/0000-0002-3341-925X
dc.authoridKaraarslan, Numan/0000-0001-5590-0637
dc.authorscopusid56250943500
dc.authorscopusid35197435300
dc.authorscopusid56674583800
dc.authorscopusid57807469200
dc.authorscopusid56884795300
dc.authorscopusid57196589837
dc.authorscopusid7005912992
dc.contributor.authorAteş, Özkan
dc.contributor.authorYılmaz, İbrahim
dc.contributor.authorKaraarslan, Numan
dc.contributor.authorErsöz, Emel
dc.contributor.authorKasim, Fatma Bahar Hacioglu
dc.contributor.authorDoğan, Mustafa
dc.contributor.authorÖzbek, Hanefi
dc.date.accessioned2023-04-20T08:01:12Z
dc.date.available2023-04-20T08:01:12Z
dc.date.issued2022
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları Ana Bilim Dalı
dc.description.abstractThe objectives of this study were to determine the prevalence of cerebrovascular diseases caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, and to assess the pharmacological agents used in such cases as reported in the literature. Patient files were retrospectively scanned to determine the prevalence of neurological symptoms of the central nervous system (headache, dizziness, lack of smell and taste, numbness in arms and legs, change in consciousness, muscle weakness, loss of urine and stool control) and cerebrovascular diseases (ischemic cerebrovascular diseases, cerebral venous sinus thrombosis, intracerebral hemorrhage, subarachnoid/subdural hemorrhage) in 2019 novel coronavirus (2019-nCoV) disease (COVID-19) cases (n = 20,099). The diagnostic laboratory, radiology examinations and treatments applied to these cases were recorded. The data from studies presenting cerebrovascular diseases associated with SARS-Cov-2, which constituted 0.035% of all cases, were systematically evaluated from electronic databases. During the treatment of cerebrovascular diseases, it was discovered that high doses of enoxaparin sodium anti-Xa are combined with apixaban or acetylsalicylic acid or clopidogrel or piracetam, and mannitol, in addition to SARS-CoV-2 treatment modalities. While neurological symptoms of the central nervous system are uncommon in cases of SARS-CoV-2 infection, cerebrovascular diseases are far less common, according to the findings of this study. Acute cerebral ischemia was discovered to be the most common cerebrovascular disease associated with SARS-CoV-2. The mortality rate increases with the association between SARS-CoV-2 and cerebrovascular disease.
dc.identifier.doi10.3855/jidc.15800
dc.identifier.endpage+
dc.identifier.issn1972-2680
dc.identifier.issue6en_US
dc.identifier.pmid35797292
dc.identifier.scopus2-s2.0-85134320811
dc.identifier.scopusqualityQ3
dc.identifier.startpage981
dc.identifier.urihttps://doi.org/10.3855/jidc.15800
dc.identifier.urihttps://hdl.handle.net/20.500.11776/10793
dc.identifier.volume16
dc.identifier.wosWOS:000825225800009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorDoğan, Mustafa
dc.language.isoen
dc.publisherJ Infection Developing Countries
dc.relation.ispartofJournal of Infection In Developing Countries
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subject2019-Ncov
dc.subjectIschemic Cerebrovascular Diseases
dc.subjectIntracerebral Hemorrhage
dc.subjectPharmacological Treatment Protocols
dc.subjectSars-Cov-2
dc.subjectInfection
dc.titleCoexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies?
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
10793.pdf
Boyut:
8.3 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text